It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
More than two million people worldwide are affected by life-threatening, invasive fungal infections annually. Candida species are the most common cause of nosocomial, invasive fungal infections and are associated with mortality rates above 40%. Despite the increasing incidence of drug-resistance, the development of novel antifungal formulations has been limited. Here we investigate the antifungal mode of action and therapeutic potential of positively charged, synthetic peptide mimics to combat Candida albicans infections. Our data indicates that these synthetic polymers cause endoplasmic reticulum stress and affect protein glycosylation, a mode of action distinct from currently approved antifungal drugs. The most promising polymer composition damaged the mannan layer of the cell wall, with additional membrane-disrupting activity. The synergistic combination of the polymer with caspofungin prevented infection of human epithelial cells in vitro, improved fungal clearance by human macrophages, and significantly increased host survival in a Galleria mellonella model of systemic candidiasis. Additionally, prolonged exposure of C. albicans to the synergistic combination of polymer and caspofungin did not lead to the evolution of tolerant strains in vitro. Together, this work highlights the enormous potential of these synthetic peptide mimics to be used as novel antifungal formulations as well as adjunctive antifungal therapy.
Fungal infections are severely underestimated as a cause of mortality, and alternative drugs are urgently needed. Here, Schaefer et al. show that a synthetic polymer mimicking defensins shows different, but synergistic activity with known antifungals.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 University of New South Wales (UNSW), School of Chemical Engineering, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); UNSW, Australian Centre for NanoMedicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); UNSW, School of Biotechnology and Biomolecular Sciences, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); Hans Knoell Institute, Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany (GRID:grid.418398.f) (ISNI:0000 0001 0143 807X)
2 Hans Knoell Institute, Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany (GRID:grid.418398.f) (ISNI:0000 0001 0143 807X)
3 Macquarie University, ARC Centre of Excellence in Synthetic Biology, School of Natural Sciences, North Ryde, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405)
4 University of New South Wales (UNSW), School of Chemical Engineering, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); UNSW, Australian Centre for NanoMedicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
5 Leibniz Lung Center, Division of Biophysics, Research Center Borstel, Borstel, Germany (GRID:grid.418187.3) (ISNI:0000 0004 0493 9170)
6 Hans Knoell Institute, Department of Biomolecular Chemistry, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany (GRID:grid.418398.f) (ISNI:0000 0001 0143 807X)
7 Jena University Hospital – Friedrich Schiller University Jena, Institute of Biochemistry I, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)
8 Hans Knoell Institute, Department of Biomolecular Chemistry, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany (GRID:grid.418398.f) (ISNI:0000 0001 0143 807X); Friedrich Schiller University Jena, Faculty of Biological Sciences, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794); Friedrich Schiller University Jena, Cluster of Excellence Balance of the Microverse, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)
9 Leibniz Lung Center, Division of Biophysics, Research Center Borstel, Borstel, Germany (GRID:grid.418187.3) (ISNI:0000 0004 0493 9170); Centre for Structural Systems Biology (CSSB), Hamburg, Germany (GRID:grid.511061.2)
10 Friedrich Schiller University Jena, Cluster of Excellence Balance of the Microverse, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794); Hans Knoell Institute, Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany (GRID:grid.418398.f) (ISNI:0000 0001 0143 807X)
11 UNSW, School of Biotechnology and Biomolecular Sciences, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)